Private Wealth Partners LLC Raises Holdings in Pfizer Inc. (NYSE:PFE)

Private Wealth Partners LLC raised its position in Pfizer Inc. (NYSE:PFE - Free Report) by 2.3% during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 593,159 shares of the biopharmaceutical company's stock after purchasing an additional 13,310 shares during the period. Pfizer accounts for approximately 1.2% of Private Wealth Partners LLC's portfolio, making the stock its 24th biggest holding. Private Wealth Partners LLC's holdings in Pfizer were worth $15,031,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of PFE. Rialto Wealth Management LLC acquired a new position in shares of Pfizer during the 4th quarter valued at about $26,000. Clarity Asset Management Inc. acquired a new position in Pfizer in the 4th quarter valued at about $27,000. Gould Capital LLC increased its holdings in shares of Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 493 shares during the last quarter. Kohmann Bosshard Financial Services LLC purchased a new stake in shares of Pfizer during the 4th quarter valued at approximately $28,000. Finally, Bernard Wealth Management Corp. acquired a new position in Pfizer in the fourth quarter valued at approximately $30,000. Hedge funds and other institutional investors own 68.36% of the company's stock.

Pfizer Stock Down 0.5%

Shares of NYSE PFE opened at $23.88 on Friday. The firm has a market cap of $135.74 billion, a P/E ratio of 17.30, a price-to-earnings-growth ratio of 0.87 and a beta of 0.57. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.96 and a current ratio of 1.26. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $31.54. The firm's 50 day moving average price is $23.22 and its 200 day moving average price is $24.91.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating the consensus estimate of $0.67 by $0.25. The firm had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The business's quarterly revenue was down 7.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.82 earnings per share. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, June 13th. Stockholders of record on Friday, May 9th were paid a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 7.20%. The ex-dividend date was Friday, May 9th. Pfizer's dividend payout ratio is currently 124.64%.

Analyst Ratings Changes

A number of research firms have commented on PFE. Cantor Fitzgerald started coverage on shares of Pfizer in a research report on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 target price on the stock. Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. UBS Group increased their price objective on shares of Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 30th. Citigroup restated a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. Finally, Guggenheim reiterated a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, four have assigned a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat, Pfizer currently has a consensus rating of "Moderate Buy" and a consensus price target of $29.17.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.